PSMA-Targeted radiopharmaceuticals: from diagnosis to risk & quality of life
- PMID: 40779069
- DOI: 10.1007/s00259-025-07507-5
PSMA-Targeted radiopharmaceuticals: from diagnosis to risk & quality of life
Conflict of interest statement
Declarations. Study-specific approval by the appropriate ethics committee for research involving humans and/or animals: Not available. Informed consent: Not required.
Similar articles
-
Diagnostic Performance of Prostate-Specific Membrane Antigen-Targeted Positron Emission Tomography in Patients Diagnosed with Different Types of Breast Cancer: A Systematic Review.Int J Mol Sci. 2024 Oct 24;25(21):11413. doi: 10.3390/ijms252111413. Int J Mol Sci. 2024. PMID: 39518965 Free PMC article.
-
Comparison of 18F-based PSMA radiotracers with [68Ga]Ga-PSMA-11 in PET/CT imaging of prostate cancer-a systematic review and meta-analysis.Prostate Cancer Prostatic Dis. 2024 Dec;27(4):654-664. doi: 10.1038/s41391-023-00755-2. Epub 2023 Nov 28. Prostate Cancer Prostatic Dis. 2024. PMID: 38017295 Free PMC article.
-
Health-related quality of life, pain, and symptomatic skeletal events with [177Lu]Lu-PSMA-617 in patients with progressive metastatic castration-resistant prostate cancer (PSMAfore): an open-label, randomised, phase 3 trial.Lancet Oncol. 2025 Jul;26(7):948-959. doi: 10.1016/S1470-2045(25)00189-5. Epub 2025 May 26. Lancet Oncol. 2025. PMID: 40441170 Clinical Trial.
-
The role of 68Ga-PSMA PET/CT scan in biochemical recurrence after primary treatment for prostate cancer: a systematic review of the literature.Minerva Urol Nefrol. 2018 Oct;70(5):462-478. doi: 10.23736/S0393-2249.18.03081-3. Epub 2018 Apr 17. Minerva Urol Nefrol. 2018. PMID: 29664244
-
Diagnostic Value of 18F-FDG and 18F-PSMA-1007 PET/CT in Bone Metastases from Prostate Cancer: Retrospective Comparative Analysis.Arch Esp Urol. 2025 Jun;78(5):572-578. doi: 10.56434/j.arch.esp.urol.20257805.77. Arch Esp Urol. 2025. PMID: 40641167
References
-
- Yu KS, Healey E, Leong TY, Kohane IS, Manrai AK. Medical artificial intelligence and human values. N Engl J Med. 2024;390:1895–904. - PubMed
-
- Kasivisvanathan V, Chan VWS, Clement KD, Levis B, Ng A, Asif A, et al. Vision: an individual patient data meta-analysis of randomised trials comparing magnetic resonance imaging targeted biopsy with standard transrectal ultrasound guided biopsy in the detection of prostate cancer. Eur Urol. 2025;87:512–23. - PubMed
-
- Dushimova Z, Iztleuov Y, Chingayeva G, Shepetov A, Mustapayeva N, Shatkovskaya O, et al. Overdiagnosis and overtreatment in prostate cancer. Dis. 2025;13:167.
-
- Cornford P, van den Bergh RCN, Briers E, Van den Broeck T, Brunckhorst O, Darraugh J, et al. EAU-EANM-ESTRO-ESUR-ISUP-SIOG guidelines on prostate cancer-2024 update. Part I: screening, diagnosis, and local treatment with curative intent. Eur Urol. 2024;86:148–63. - PubMed
Publication types
LinkOut - more resources
Full Text Sources
Miscellaneous